The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...
The angiotensin II type 1 receptor antagonist (angio-tensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to ...
Losartan potassium is marketed as a single-ingredient ... The combination product should also be avoided in patients with renal impairment (creatinine clearance [CL cr], <30 mL/min).
Arbli is supplied as an peppermint-flavored oral suspension containing 10mg/mL of losartan potassium in 165mL bottles. The Food and Drug Administration (FDA) has approved Arbli ™, an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback